MARKET

CELG

Celgene
CELG
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
19.84
4.606
6.37
77,001,936,000.00
News
Financial
Releases
Corp Actions
Analysis
Profile
Jounce Therapeutics: An Undervalued Biotech Flush With Big Pharma Cash
Jounce therapeutics is a differentiated player in the hot immuno-oncology sector.JNCE stock has not been fairly priced after its newly struck partnership with Gilead Sciences, making it a compelling buy for the short term.JNCE's drug discovery engine continues to impress, potentially making it an equally compelling pick for the longer term.
Seekingalpha · 09/11 18:06
Biotech IPO Nkarta triples in debut
Seeking Alpha - Article · 07/10 16:45
Nurix Therapeutics Files For U.S. IPO
Seeking Alpha - Article · 07/08 19:01
IPO Update: Nkarta Proposes Terms For $150 Million IPO
Seeking Alpha - Article · 07/05 16:05
Karyopharm Stock Down From Peak Despite Commercial Progress And Strong Data Provides Investor Opportunity
Seeking Alpha - Article · 06/24 13:48
Greenwich LifeSciences Files For U.S. IPO
Seeking Alpha - Article · 06/17 16:44
AstraZeneca contacted Gilead over potential megamerger
Britain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies.
Reuters · 06/08 13:09
These 4 Biotech Stocks Are Outperforming Their Peers — Here's Why
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.
Investor's Business Daily · 06/02 14:00
More
No Data
Learn about the latest financial forecast of CELG. Analyze the recent business situations of Celgene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CELG stock price target is 104.00 with a high estimate of 116.00 and a low estimate of 86.00.
EPS
Institutional Holdings
Institutions: 1.39K
Institutional Holdings: 536.66M
% Owned: 75.44%
Shares Outstanding: 711.40M
TypeInstitutionsShares
Increased
328
54.08M
New
74
2.28M
Decreased
607
50.75M
Sold Out
163
22.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Chief Executive Officer/Director
Mark Alles
Chief Financial Officer/Executive Vice President
David Elkins
Corporate Executive
Nadim Ahmed
Corporate Executive
Terrie Curran
Corporate Executive
Alise Reicin
Corporate Executive
Rupert Vessey
Executive Vice President/General Counsel
Jonathan Biller
Executive Vice President
Peter Kellogg
Lead Director
Michael Casey
Director
Hans Bishop
Independent Director
Richard Barker
Director
Patricia Hall
Independent Director
Michael Bonney
Independent Director
Carrie Cox
Independent Director
Michael Friedman
Independent Director
Julia Haller
Independent Director
Patricia Hemingway Hall
Independent Director
James Loughlin
Independent Director
Ernest Mario
Independent Director
John Weiland
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Celgene stock information, including NASDAQ:CELG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CELG stock methods without spending real money on the virtual paper trading platform.